1 / 3

Sodium Phenylbutyrate Drugs Market to Witness Widespread Expansion by 2030

Sodium phenylbutyrate drugs are prescribed for adjunctive therapy in the chronic management of urea cycle disorders. They are primarily administered orally, in equally divided doses, with each meal or feeding. Divalproex (Depakote), haloperidol (Haldol), valproic acid (Depakene, Stavzor) may interact with sodium phenylbutyrate, if taken simultaneously. Buphenyl is a brand name of sodium phenylbutyrate, approved by the FDA.<br><br>

11425
Download Presentation

Sodium Phenylbutyrate Drugs Market to Witness Widespread Expansion by 2030

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Sodium Phenylbutyrate Drugs Market: Introduction Sodium phenylbutyrate drugs are prescribed for adjunctive therapy in the chronic management of urea cycle disorders. They are primarily administered orally, in equally divided doses, with each meal or feeding. Divalproex (Depakote), haloperidol (Haldol), valproic acid (Depakene, Stavzor) may interact with sodium phenylbutyrate, if taken simultaneously. Buphenyl is a brand name of sodium phenylbutyrate, approved by the FDA. Read Report Overview - https://www.transparencymarketresearch.com/sodium-phenylbutyrate-drugs- market.html Key Drivers and Restraints of Global Sodium Phenylbutyrate Drugs Market Urea cycle disorders (UCDs) are inborn errors of metabolism (IEMs) resulting from defects in any 1 of the six enzymes or 2 transporters involved in the hepatic removal of ammonia from the bloodstream by conversion to urea, which is excreted by the kidneys. UCDs include carbamoyl phosphate synthase (CPS) deficiency, ornithine transcarbamylase (OTC) deficiency, argininosuccinate synthetase deficiency (citrullinemia), argininosuccinate lyase deficiency (argininosuccinic aciduria), and arginase deficiency (argininemia). Overall incidence of UCD, globally, varies from 1:8000 to 1:44,000 births. An estimated cumulative incidence of UCDs in Europe is approximately 1 in 51,946. Sodium phenylbutyrate drugs are utilized for the treatment of urea cycle disorders. Thus, an increase in cases of UCDs fuel the market. Increased research & development initiatives undertaken by research & academic institutes supported by pharmaceutical companies as well as governments are estimated to drive sodium phenylbutyrate drugs market Side effects related to the intake of sodium phenylbutyrate drugs may hamper the market. Common side effects may include missed menstrual periods or changes in the regular cycle, loss of appetite, headache, nausea or vomiting, lower back, side, or stomach pain. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79557 Oral Segment Witness Highest Growth Based on route of administration, the global sodium phenylbutyrate drugs market can be divided into oral and nasogastric intubation The oral segment accounted for a prominent share of the market in 2019. Sodium phenylbutyrate is available in tablet or powder form. Nasogastric intubation involves the insertion of a plastic tube through the nose, past the throat, and down into the stomach. Nasogastric tube (NGT) insertion is done through anesthetized procedure for critically ill patients who cannot swallow a tablet through oral intake. Hospital Pharmacies to Dominate Global Sodium Phenylbutyrate Drugs Market Based on distribution channel, the global sodium phenylbutyrate drugs market can be divided into: hospital pharmacies, online and retail pharmacies In terms of revenue, the hospital pharmacies segment accounted for a notable share of the global market in 2019, followed by the retail pharmacies segment. Within a hospital, the

  2. hospital pharmacy dispenses inpatient medications. Hospital pharmacies usually stock a larger range of medications. Expansion of hospital pharmacies is attributed to offering quality medicines to patient by purchasing directly from drug manufacturers, thus preventing the issues of counterfeit medicines. The online segment is estimated to expand at a significant CAGR during the forecast period. Increasing penetration of internet, worldwide, rising investments made by private companies, and an increase in the number of steps taken by government bodies are major factors propelling the segment Request for Analysis of COVID-19 Impact on Sodium Phenylbutyrate Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79557 North America to Dominate Global Sodium Phenylbutyrate Drugs Market In terms of region, the global sodium phenylbutyrate drugs market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa In terms of revenue, North America dominated the sodium phenylbutyrate drugs market. Increase in incidence of urea cycle disorders, rise in number of FDA approvals, and continuous merger & acquisition between companies contribute to the leading share held by the region. According to data published in NCBI in 2013, incidence of urea cycle disorders is at 1 in 35,000 live births in the U.S. or about 113 new patients per year. The sodium phenylbutyrate drugs market in Asia Pacific is anticipated to be driven by an increase in the number of target patients, rise in healthcare expenditure, and investments by various companies in research & development activities in the region. Pre Book Sodium Phenylbutyrate Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79557&ltype=S Key Manufacturers Operating in Market The global sodium phenylbutyrate drugs market was highly fragmented in 2019. Key manufacturers operating in the global market are: Horizon Therapeutics USA, Inc. Par Pharm Sigmapharm Labs LLC Alvogen SEQENS GROUP Bausch Health Companies, Inc. More Trending Reports by Transparency Market Research – Primary Immunodeficiency Market: https://www.biospace.com/article/primary-immunodeficiency- market-advancements-in-genetic-management-and-next-generation-sequencing-technologies-to-aid- market-growth/

  3. Pressure Relief Devices Market: https://www.prnewswire.com/news-releases/shining-growth- prospects-in-pipeline-for-pressure-relief-devices-market-on-back-of-surging-demand-for-foam-based- mattresses-says-tmr-301113102.html About Us Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

More Related